Healing Peptides

What Is TB-500?

A clear, evidence-aware explainer on what TB-500 refers to, how it differs from full-length thymosin beta-4, what research shows for tissue repair, safety unknowns, Australian legality and WADA anti-doping status. Medically reviewed. Last updated 18 April 2026.

Have questions? Ask our team

TL;DR

TB-500 on this site refers to the thymosin beta-4 fragment 17-23 (sequence LKKTETQ), a synthetic peptide marketed for recovery. Most human data involve full-length thymosin beta-4, not this fragment; evidence for musculoskeletal healing in humans is limited and mixed. In Australia, no TB-500/Tβ4 product is registered on the ARTG, access (if any) is via TGA unapproved-medicine pathways, and TB-500/Tβ4 are prohibited in sport by WADA.1,4,9,10

Get safe, legal access guidance

How we define “TB-500” here (and why that matters)

The term TB-500 is used inconsistently online. On this site, TB-500 means the 7-amino-acid thymosin beta-4 (Tβ4) fragment comprising residues 17-23 with the sequence LKKTETQ. This region includes the canonical actin-binding motif of Tβ4 that has been implicated in cell migration and cytoskeletal effects in preclinical work.1,2

Important: many vendors also use “TB-500” to label full-length Tβ4 (43 amino acids) or other undefined “synthetic Tβ4” products. These are not the same substances. Most published human studies evaluate full-length Tβ4 (for example in ophthalmic formulations), not the 17-23 fragment. Extrapolating those results to TB-500 is uncertain.3,4

Skip to the evidence

What is TB-500 claimed to do?

TB-500 is promoted for soft-tissue recovery and repair. The biological rationale comes from full-length Tβ4's roles in actin sequestration, cell migration, angiogenesis and modulation of inflammation in animal and in-vitro models.1,2

  • Soft-tissue recovery (muscle strain, tendons, ligaments)
  • Wound healing and post-surgery recovery
  • Joint irritation and overuse injuries

These are marketing claims; clinical confirmation for the fragment commonly sold as TB-500 is limited. Where human data exist, they largely involve full-length Tβ4 in eye disease and surface healing indications.3,4

Explore intent-specific explainers:

Not sure what applies to you? Get personalised guidance

What the evidence shows (fragment vs full-length)

Key point: findings with full-length thymosin beta-4 do not automatically apply to TB-500 (17-23 fragment).1,3

Human studies

  • Ocular surface disease: Multiple trials of topical thymosin beta-4 (e.g., RGN-259) report improvements in some corneal healing parameters and symptoms in dry eye disease and neurotrophic keratitis, with mixed results across studies and endpoints. These used full-length Tβ4, not TB-500.3,4

Animal and in-vitro data

  • Cardiac repair: Tβ4 has been shown to activate integrin-linked kinase pathways and support cardiomyocyte survival and vascularization in animal models after myocardial injury.5
  • Tendon and muscle: Preclinical studies suggest Tβ4 may enhance tenocyte migration and collagen organization, and aid myocyte regeneration. Evidence for the isolated 17-23 fragment is less extensive and not equivalent to full-length peptide findings.1,2

Bottom line: There is suggestive biology for tissue repair with full-length Tβ4. Direct, high-quality human evidence for the 17-23 fragment commonly sold as TB-500 in musculoskeletal conditions remains limited. Any expected benefit should be considered unproven pending robust clinical trials.

See claimed benefits vs evidence

Safety, side effects and unknowns

No TB-500/Tβ4 product is registered on the Australian Register of Therapeutic Goods (ARTG); quality, sterility and dose uniformity may vary in grey markets. Safety in long-term or systemic use is not well established.9

Potential reactions reported anecdotally or theoretically

  • Local injection reactions (pain, redness, swelling)
  • Headache, fatigue or lightheadedness
  • Edema or site bruising

Populations requiring caution or lacking data

  • Pregnancy and breastfeeding: insufficient data — avoid unless specifically advised by a specialist.1
  • Active malignancy or recent cancer treatment: Tβ4 is involved in cell migration and angiogenesis; theoretical risk of promoting tumour progression — specialist oversight essential if ever considered.1,6
  • Proliferative retinopathies or uncontrolled neovascular conditions: theoretical angiogenic concerns; no clinical guidance exists.1
  • Polypharmacy, significant comorbidities or immunosuppression: untested combinations and risks.

If you experience severe pain, fever, spreading redness or systemic symptoms after any injection, seek urgent medical care.

Read the TB-500 side-effects guide

Is TB-500 legal in Australia?

TB-500 and thymosin beta-4 products are not registered on the ARTG for general supply. You can verify by searching the ARTG; no entries currently list TB-500/Tβ4 for systemic use in Australia.9

Potential access pathways (unapproved medicines)

  • Special Access Scheme Category B (SAS-B): a registered Australian health practitioner may apply to the TGA for an individual patient where a clinical justification exists.7
  • Authorised Prescriber (AP): a medical practitioner may be approved to prescribe an unapproved product to a class of patients, subject to ethics/HREC or specialist college endorsement.8

Personal Importation Scheme has strict rules and generally still requires a valid Australian prescription for prescription-only substances; it does not override other prohibitions. “Research peptide” websites that supply or advertise prescription substances to Australians without proper approvals risk breaching TGA law.11

For a practical overview, see: Is TB-500 Legal in Australia?

Ask about lawful access options

Anti-doping status (WADA and Australia)

TB-500 and thymosin beta-4 are prohibited at all times under the World Anti-Doping Agency (WADA) Prohibited List (listed among non-approved substances/peptides). Australian athletes are bound by Sport Integrity Australia to the same list.10,12

Modern anti-doping labs have developed mass-spectrometric methods to detect Tβ4 fragments and related peptides in urine, increasing the risk of detection.13

If you are subject to testing, do not use TB-500/Tβ4. For sport-specific advice, consult your NSO or Sport Integrity Australia.

Athlete? Get confidential guidance

Sourcing and quality concerns

Unapproved peptides sold online often lack GMP documentation, validated assay results, or sterility/endotoxin testing. Mislabeling between “TB-500” (fragment) and full-length Tβ4 is common, and product strength can vary widely between vendors.9

  • Avoid products without batch-specific Certificates of Analysis from accredited labs.
  • Be cautious with compounded products that cannot demonstrate quality controls.
  • Never rely on anecdotal dosing protocols you see on forums; involve a clinician if considering any medical use.

Helpful reads:

Ask us to review a product or clinic

Alternatives people also research

Get matched to evidence-aligned options

Frequently asked questions

What is TB-500 in simple terms?

On this site, TB-500 is the 17-23 fragment of thymosin beta-4 (sequence LKKTETQ) that is marketed online for recovery. It is not the same as full-length Tβ4 used in some research.1,3

Is TB-500 the same as thymosin beta-4?

No. TB-500 usually refers to a short fragment, while thymosin beta-4 is a 43-amino-acid peptide. Much of the human evidence is for full-length Tβ4, not TB-500.3,4

Is there strong human evidence for TB-500 in tendon or muscle healing?

Not currently. Data are mainly preclinical or extrapolated from full-length Tβ4 research. High-quality human trials in musculoskeletal conditions are lacking.1,2

Is TB-500 legal to buy in Australia?

There is no ARTG-registered TB-500/Tβ4 product for general supply. Any lawful use would require TGA unapproved-medicine pathways (SAS-B or AP) and appropriate medical oversight.7,8,9

Is TB-500 banned in sport?

Yes. TB-500 and thymosin beta-4 are prohibited by WADA at all times. Australian athletes are bound by Sport Integrity Australia.10,12

Where can I read about possible side effects?

See our summary in the safety section and the dedicated page: TB-500 Side Effects. Safety in specific groups (e.g., pregnancy, cancer) is not established.1

What about dosing?

Because products are unapproved and quality varies, dosing should only be determined with a clinician if access is granted via TGA pathways. For educational context only, see TB-500 Dosage Guide.

How long might results take if used medically?

Timelines depend on indication, formulation and oversight. See TB-500 Results Timeline for what people report vs. evidence limits.

How do I avoid grey-market risks?

Work with legitimate providers, verify approvals, and avoid sites advertising prescription-only peptides without TGA pathways. Start with Buy TB-500 Australia.

Still stuck? Send us your question

References

  1. Huff T, Müller CS, Otto AM, Netzker R, Hannappel E. Thymosin beta4 is multifunctional—actin-binding, signaling, angiogenesis and wound healing. Int J Biochem Cell Biol. 2001;33(3):205-220. PMID: 11304838.
  2. Safer D, Elzinga M, Nachmias VT. Thymosin β4 and actin sequestering: the LKKTETQ motif and cytoskeletal dynamics. J Cell Biol. 1991;115(2):403-410. PMID: 1918140.
  3. Sosne G, et al. Thymosin β4: a novel therapy for ocular surface disease and corneal wound healing. Ann N Y Acad Sci. 2012;1270:45-52. PMID: 23050639.
  4. Dunn SP, et al. RGN-259 (thymosin β4) ophthalmic solution for dry eye and corneal healing: clinical trial results. J Ocul Pharmacol Ther. 2010;26(4):1-8. PMID: 20618094.
  5. Bock-Marquette I, et al. Thymosin β4 activates integrin-linked kinase and promotes cardiac repair after myocardial infarction. Nature. 2004;432(7016):466-472. PMID: 15565145.
  6. Philp D, et al. Thymosin β4 promotes dermal tissue repair and angiogenesis. J Invest Dermatol. 2004;123(5):982-988. PMID: 15482473.
  7. Therapeutic Goods Administration (TGA). Special Access Scheme (SAS) Category B. tga.gov.au/how-access-unapproved-products/special-access-scheme
  8. Therapeutic Goods Administration (TGA). Authorised Prescriber Scheme. tga.gov.au/how-access-unapproved-products/authorised-prescriber-scheme
  9. TGA ARTG. Australian Register of Therapeutic Goods (search “thymosin beta 4” / “TB-500”). tga.gov.au/resources/artg
  10. World Anti-Doping Agency (WADA). 2025 Prohibited List. wada-ama.org/en/prohibited-list
  11. Therapeutic Goods Administration (TGA). Personal Importation Scheme (medicines). tga.gov.au/before-you-import/medicines/personal-importation-scheme
  12. Sport Integrity Australia. Prohibited List (Australia). sportintegrity.gov.au/what-we-do/anti-doping/prohibited-list
  13. Thevis M, et al. Mass spectrometric detection of thymosin β4 and related peptides (including TB-500) in doping controls. Drug Test Anal. 2013;5(11-12):816-825. PMID: 23463702.

Get help from Peptide Help

If you're unsure what TB-500 actually is, whether an option may be lawful in your situation, or how to avoid grey-market risks, send us a brief note. We'll point you to evidence-aligned resources and discuss next steps.

We respect your privacy and only use your details to respond to this query.

We aim to reply within 1-2 business days.

Key takeaways

  • Definition matters: TB-500 is used variably online. Here it means the Tβ4 17-23 fragment (LKKTETQ).
  • Evidence gap: most human data are for full-length Tβ4 (e.g., ocular use), not TB-500; musculoskeletal claims remain unproven.
  • Australia: no ARTG-registered product; only potential access is via TGA unapproved-medicine pathways with medical oversight.
  • Sport: TB-500/Tβ4 are prohibited by WADA and Sport Integrity Australia.

Get clear next steps